Süllentrop F, Moka D, Neubauer S, Haupt G, Engelmann U, Hahn J, Schicha H
Institute of Inorganic Chemistry, University of Cologne, Cologne, Germany.
NMR Biomed. 2002 Feb;15(1):60-8. doi: 10.1002/nbm.758.
Advanced renal cell carcinoma (RCC) has a poor prognosis and is characterized by an unpredictable clinical course. The aim of this study was to assess the systemic phospholipid distribution as a possible marker of tumor stage and tumor spread beyond the kidney. To this end, the effect of renal cell carcinoma (RCC) on phospholipid concentrations in blood plasma using 31P NMR spectroscopy was studied in: (a) 29 patients with RCC prior to nephrectomy; (b) 19 healthy volunteers; (c) three patients with other renal tumors (renal metastases of bronchial carcinoma and of renal pelvic carcinoma, and a benign renal tumor). Furthermore, the phospholipid concentrations of eight patients of group (a) were determined 6 months after nephrectomy, when they were in remission. We found considerable deviations in the concentrations of the lysophosphatidylcholines (LPC1, LPC2) in both male and female patients with RCC compared to healthy volunteers (male--LPC1 0.217+/-0.062 vs 0.297+/-0.049 mmol/l, LPC2 0.036+/-0.014 vs 0.068+/-0.024 mmol/l; female--LPC1 0.195+/-0.071 vs 0.296+/-0.044 mmol/l, LPC2 0.037+/-0.027 vs 0.044+/-0.014 mmol/l). In addition, female patients with RCC showed lower concentrations of phosphatidylcholines (PC; 1.409+/-0.268 vs 1.947+/-0.259 mmol/l). The low phospholipid concentrations normalized for patients in remission. Phospholipid concentrations were found to depend on tumor stage and metastatic spread. The deviations in phospholipid concentrations (LPC1, LPC2, PC) observed may be attributable to systemic effects caused by the tumor as well as changes in enzyme activities.
晚期肾细胞癌（RCC）预后较差，其临床病程难以预测。本研究的目的是评估全身磷脂分布情况，将其作为肿瘤分期及肿瘤扩散至肾脏以外的一个可能标志物。为此，我们采用³¹P核磁共振波谱法研究了肾细胞癌（RCC）对血浆中磷脂浓度的影响，研究对象包括：（a）29例肾切除术前的RCC患者；（b）19名健康志愿者；（c）3例患有其他肾脏肿瘤的患者（支气管癌和肾盂癌的肾转移瘤以及1例良性肾肿瘤）。此外，对（a）组中8例患者在肾切除术后6个月病情缓解时的磷脂浓度进行了测定。我们发现，与健康志愿者相比，男性和女性RCC患者的溶血磷脂酰胆碱（LPC1、LPC2）浓度均有显著差异（男性——LPC1 0.217±0.062 vs 0.297±0.049 mmol/L，LPC2 0.036±0.014 vs 0.068±0.024 mmol/L；女性——LPC1 0.195±0.071 vs 0.296±0.044 mmol/L，LPC2 0.037±0.027 vs 0.044±0.014 mmol/L）。此外，女性RCC患者的磷脂酰胆碱（PC）浓度较低（1.409±0.268 vs 1.947±0.259 mmol/L）。病情缓解患者的低磷脂浓度恢复正常。研究发现磷脂浓度取决于肿瘤分期和转移扩散情况。观察到的磷脂浓度（LPC1、LPC2及PC）偏差可能归因于肿瘤引起的全身效应以及酶活性的变化。
